Medigene AG (HAM:MDG1) EBITDA Margin %: -132.64% (As of Jun. 2024)


HAM:MDG1 Medigene AG HAM:MDG1
12 GF Score
Price €0.02
View Full Analysis

What is Medigene AG EBITDA Margin %?

Medigene AG HAM:MDG1 12 EBITDA Margin % is -132.64% as of Jun. 2024. GuruFocus rates HAM:MDG1 with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medigene AG's EBITDA for the six months ended in Jun. 2024 was €-5.94 Mil. Medigene AG's Revenue for the six months ended in Jun. 2024 was €4.48 Mil. Therefore, Medigene AG's EBITDA margin for the quarter that ended in Jun. 2024 was -132.64%.

Medigene AG  (HAM:MDG1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Medigene AG EBITDA Margin % Related Terms

Medigene AG EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Medigene AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG EBITDA Margin % Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -160.80 -268.72 -62.04 42.04 -241.65

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.75 -37.28 -218.73 -265.29 -132.64

HAM:MDG1 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Medigene AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Medigene AG's EBITDA Margin % falls into.


HAM:MDG1
12GF Score
Medigene AG HAM:MDG1
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Medigene AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-14.581/6.034
=-241.65 %

Medigene AG's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-5.937/4.476
=-132.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -132.64% mean?
Medigene AG (HAM:MDG1) has a EBITDA Margin % of -132.64% as of Jun. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medigene AG and its competitors.
Is Medigene AG's EBITDA Margin % too high?
Medigene AG's current EBITDA Margin % is -132.64%. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's EBITDA Margin % compare to VRTX and REGN?
Medigene AG's EBITDA Margin % of -132.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medigene AG and its competitors. Medigene AG's current EBITDA Margin % is -132.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (HAM:MDG1) has a current EBITDA Margin % of -132.64%. The current EBITDA Margin % is -132.64%. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medigene AG (HAM:MDG1), the current EBITDA Margin % is -132.64% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for HAM:MDG1

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price